CRIS CURIS INC
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1108205 · Fiscal year ends 12/31
Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-36.9%
TTM net income YoY49.8%
TTM EPS YoY90.5%
Revenue 3-yr CAGR-12.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-100.2%
Net margin-299.7%
FCF margin—
EBITDA margin-98.5%
Returns
ROE-693.9%
ROA-61.3%
ROIC (approx.)—
Asset turnover0.20x
Leverage & solvency
Liabilities / assets57.2%
Debt / equity0.00x
Current ratio1.11x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.37x
Accruals ratio22.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | $0 | $0 | $1.14M | $3.18M | $2.75M | $2.38M | $3.35M |
| R&D expense | $5.59M | $6.71M | $6.45M | $5.83M | $6.43M | $7.46M | $8.54M | $8.97M |
| SG&A expense | $3.15M | $3.23M | $5.07M | $2.88M | $3.65M | $3.53M | $3.98M | $3.35M |
| Operating income | -$8.75M | -$9.94M | -$11.52M | $19.62M | -$6.92M | -$8.25M | -$10.16M | -$8.99M |
| Net income | -$8.12M | -$8.58M | -$24.20M | $19.36M | -$7.73M | -$8.59M | -$10.62M | -$9.62M |
| EBITDA | -$8.74M | -$9.93M | -$11.51M | $19.66M | -$6.89M | -$8.21M | -$10.10M | -$8.98M |
| EPS (basic) | -1.94 | -4.02 | -1.25 | — | -9.86 | -13.61 | -1.25 | — |
| EPS (diluted) | -1.94 | -4.02 | -1.25 | — | -9.86 | -13.61 | -1.25 | — |
| Weighted avg. shares (diluted) | 4.18M | 2.14M | 19.36M | — | 784,109 | 631,475 | 8.49M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $5.01M | $5.07M | $15.00M | $5.06M | $9.05M | $10.14M | $20.28M | $20.54M |
| Short-term investments | — | — | — | — | — | — | — | $0 |
| Receivables | — | — | — | $0 | $3.24M | $2.75M | $2.31M | $3.35M |
| Current assets | $6.92M | $6.72M | $16.61M | $6.92M | $13.91M | $14.42M | $24.81M | $26.39M |
| PP&E, net | $36,000 | $46,000 | $54,000 | $62,000 | $98,000 | $130,000 | $172,000 | $231,000 |
| Goodwill | $8.98M | $8.98M | $8.98M | $8.98M | $8.98M | $8.98M | $8.98M | $8.98M |
| Total assets | $18.80M | $18.97M | $29.69M | $19.97M | $27.64M | $29.23M | $39.33M | $41.27M |
| Current liabilities | $16.25M | $13.68M | $14.97M | $14.08M | $19.91M | $19.37M | $20.12M | $19.03M |
| Short-term debt | — | — | — | $0 | $6.95M | $7.35M | $7.23M | $7.56M |
| Total liabilities | $16.25M | $14.28M | $16.98M | $14.50M | $42.33M | $43.22M | $45.93M | $47.26M |
| Shareholders' equity | $2.55M | $4.70M | $12.71M | $5.46M | -$14.69M | -$13.99M | -$6.61M | -$6.00M |
| Shares outstanding | 4.10M | 1.95M | 39.98M | 646,537 | 12.73M | 10.71M | 10.46M | 8.49M |
| Cash flow statement | ||||||||
| Operating cash flow | -$5.75M | -$9.65M | -$9.00M | -$6.37M | -$5.57M | -$8.01M | -$7.25M | -$9.26M |
| Investing cash flow | — | $0 | $0 | $2.50M | $0 | $0 | $0 | -$428,000 |
| Financing cash flow | $5.69M | -$282,000 | $18.94M | -$119,000 | $4.48M | -$2.13M | $7.54M | $8.83M |
| Depreciation & amortization | $10,000 | $8,000 | $8,000 | $36,000 | $32,000 | $42,000 | $59,000 | $16,000 |
| Stock-based compensation | $526,000 | $569,000 | $575,000 | $795,000 | $924,000 | $1.14M | $1.16M | $1.28M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.